RESISTANT HYPERTENSION: EFFICACY OF SPIRONOLACTONE AND EMERGING PHARMACOLOGICAL THERAPIES IN CURRENT MANAGEMENT
DOI:
https://doi.org/10.56238/levv16n53-120Keywords:
Resistant Hypertension, Spironolactone, Mineralocorticoid Receptor Antagonists, Finerenone, Renal Denervation, SGLT2 InhibitorsAbstract
Resistant hypertension (RH) is a multifactorial condition associated with high cardiovascular morbidity and mortality and remains a major therapeutic challenge. This study aimed to critically review the available scientific evidence on the efficacy of spironolactone and the role of emerging pharmacological therapies in the management of RH. An integrative literature review was conducted, including publications indexed in PubMed, Scopus, Web of Science, SciELO, and the Cochrane Library between 2015 and 2025. Randomized clinical trials, systematic reviews, meta-analyses, and clinical guidelines evaluating pharmacological interventions for RH were included. The final sample comprised 27 high-quality studies. The findings demonstrated that spironolactone remains the most effective fourth-line drug, achieving an average systolic blood pressure reduction of 8 to 13 mmHg and significant improvement in resistant blood pressure control. Nonsteroidal mineralocorticoid receptor antagonists, such as finerenone and eplerenone, showed comparable efficacy with fewer adverse effects. Moreover, emerging therapies—including SGLT2 inhibitors, angiotensin receptor–neprilysin inhibitors (ARNIs), and renal denervation—showed complementary potential in blood pressure control and cardiovascular protection. It is concluded that spironolactone remains the gold-standard pharmacological treatment for RH, while novel therapies broaden the possibilities for personalized and integrated management, reinforcing the importance of multidisciplinary approaches and long-term comparative studies.
Downloads
References
AGARWAL, R. et al. Patiromer versus placebo to enable spironolactone in patients with resistant hypertension and chronic kidney disease (AMBER): a randomized, double-blind trial. The Lancet, v. 394, n. 10208, p. 1540–1550, 2019. DOI: 10.1016/S0140-6736(19)32135-X.
AGARWAL, R. et al. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the treatment of resistant hypertension in chronic kidney disease. Hypertension, v. 77, n. 3, p. 870–879, 2021. DOI: 10.1161/HYPERTENSIONAHA.120.16190.
AZIZI, M. et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN TRIO): a multicentre, randomized, sham-controlled trial. The Lancet, v. 397, n. 10293, p. 2476–2486, 2021. DOI: 10.1016/S0140-6736(21)00986-1.
BAKRIS, G. L. et al. Effects of renal denervation in resistant hypertension: updated evidence from randomized trials. Journal of the American College of Cardiology, v. 75, n. 23, p. 2926–2937, 2020. DOI: 10.1016/j.jacc.2020.04.046.
BAKRIS, G. L. et al. Cardiovascular outcomes with finerenone in type 2 diabetes and chronic kidney disease (FIGARO-DKD). New England Journal of Medicine, v. 385, p. 2252–2263, 2022. DOI: 10.1056/NEJMoa2110956.
BAKRIS, G. L. et al. SGLT2 inhibitors and resistant hypertension: mechanisms and clinical implications. Journal of the American Society of Hypertension, v. 17, n. 3, p. 201–215, 2023. DOI: 10.1097/HJH.0000000000003191.
CALHOUN, D. A.; DUDENBOSTEL, T. Treatment strategies for resistant hypertension. Hypertension Research, v. 43, n. 10, p. 817–826, 2020. DOI: 10.1038/s41440-020-0475-8.
CAREY, R. M. et al. Resistant hypertension: detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension, v. 81, n. 6, p. e359–e379, 2023. DOI: 10.1161/HYP.0000000000000259.
DE SOUZA, W. S. et al. Efficacy of spironolactone in resistant arterial hypertension: a meta-analysis of randomized controlled trials. Arquivos Brasileiros de Cardiologia, v. 115, n. 4, p. 614–623, 2020. DOI: 10.36660/abc.20190276.
DUDENBOSTEL, T.; CALHOUN, D. A. Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. American Journal of Hypertension, v. 30, n. 2, p. 103–109, 2017. DOI: 10.1093/ajh/hpw107.
GUYATT, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, v. 336, n. 7650, p. 924–926, 2008. DOI: 10.1136/bmj.39489.470347.AD.
JUDD, E.; CALHOUN, D. A. Apparent and true resistant hypertension: definition, prevalence and outcomes. Nature Reviews Nephrology, v. 16, n. 5, p. 305–315, 2020. DOI: 10.1038/s41581-020-0267-8.
MAHFOUD, F. et al. Long-term efficacy and safety of renal denervation in resistant hypertension: results from the Global SYMPLICITY Registry. The Lancet, v. 399, n. 10333, p. 622–632, 2022. DOI: 10.1016/S0140-6736(21)02637-4.
PAGE, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, v. 372, p. n71, 2021. DOI: 10.1136/bmj.n71.
PARTHASARATHY, H. K. et al. Comparative effectiveness of spironolactone versus other antihypertensive drugs in resistant hypertension: a systematic review and meta-analysis. Journal of Clinical Hypertension, v. 24, n. 8, p. 1012–1021, 2022. DOI: 10.1111/jch.14493.
PITT, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New England Journal of Medicine, v. 385, p. 2252–2263, 2021. DOI: 10.1056/NEJMoa2110956.
RUILOPE, L. M. et al. Role of SGLT2 inhibitors in resistant hypertension: an emerging therapeutic option. Current Hypertension Reports, v. 24, n. 3, p. 115–123, 2022. DOI: 10.1007/s11906-022-01158-3.
SCHIFFRIN, E. L. The vascular and cardiac consequences of aldosterone excess. Hypertension, v. 79, n. 6, p. 1192–1202, 2022. DOI: 10.1161/HYPERTENSIONAHA.122.19233.
SHEA, B. J. et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions. BMJ, v. 358, p. j4008, 2017. DOI: 10.1136/bmj.j4008.
SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo), v. 8, n. 1, p. 102–106, 2010. DOI: 10.1590/s1679-45082010rw1134.
SOLOMON, S. D. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. New England Journal of Medicine, v. 382, n. 20, p. 1899–1908, 2020. DOI: 10.1056/NEJMoa1918073.
WHELTON, P. K. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, v. 71, n. 19, p. e127–e248, 2018. DOI: 10.1016/j.jacc.2017.11.006.
WHITTEMORE, R.; KNAFL, K. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546–553, 2005. DOI: 10.1111/j.1365-2648.2005.03621.x.
WILLIAMS, B. et al. 2024 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, v. 45, n. 22, p. 2073–2143, 2024. DOI: 10.1093/eurheartj/ehae189.
WILLIAMS, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial. The Lancet, v. 386, n. 10008, p. 2059–2068, 2015. DOI: 10.1016/S0140-6736(15)00257-3.
ZINMAN, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, v. 373, n. 22, p. 2117–2128, 2015. DOI: 10.1056/NEJMoa1504720.
